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Effect of dialysate calcium concentration on bone disease in
patients on hemodialysis. Plasma biochemistry, bone radiology and
morphometry were studied in a group of 20 patients receiving
maintenance hemodialysis. The aim was to determine if increasing
the dialysate calcium concentration would decrease plasma para-
thyroid hormone and improve the radiologic appearances of bone
in patients without producing serious side effects. Dialysate cal-
cium concentration was increased stepwise from 4.5 to 6.0 and then
to 7.0 mg/I00 ml. Mean predialysis plasma calcium concentration
increased from 9.4 to 9.7 and then to 10.0 mg/lOU ml and mean
predialysis phosphate concentration increased from 5.3 to 5.6
mg/lOO ml. Parathyroid hormone concentration was elevated in all
patients but the mean concentration did not change significantly
although in seven patients a decrease occurred. Six patients had
radiologic signs of renal bone disease, two patients showed im-
provement and three patients developed bone disease during the
study. The patients with radiologic bone disease had the highest
parathyroid hormone concentrations and the majority were fe-
male. Morphometric bone measurements showed that bone loss
during the study occurred mainly in the male patients. Soft tissue
calcification continued to appear during the study. Although the
response of some patients to an increased dialysate calcium con-
centration was favorable, it was impossible to predict which type of
patient would benefit from the use of a dialysate calcium concen-
tration of 7,0 mg/lOO ml.
Effet de Ia concentration en calcium du dialysat sur I'ostéopathie
des malades en hémodialyse. L'étude a porte sur un groupe de 20
malades en hemodialyse chronique et a compris les determinations
plasmatiques Ia radiologie et Ia morphométrie osseuses. Le but
était de determiner Si l'augmentation de Ia concentration de cal-
cium dans le dialysat peut dimineur Ia concentration plasmatique
d'hormone parathyroldienne et amCliorer l'aspect radiologique de
l'os sans produire d'effets secondaires importants. La concentra-
tion de calcium dans le dialysat a été augmentée par paliers de 4,5 a
6,0 puis a 7.0 mg/l00 ml. La concentration plasmatique moyenne
de calcium avant Ia dialyse a augmenté de 9,4 a 9,7 puis a 10,0
mg/l00 ml et Ia concentration plasmatique moyenne de phosphate
de 5,3 a 5,6 mg/lOU ml. La concentration d'hormone para-
thyroIdienne était élevée chez tous les malades mais Ia concentra-
tion moyenne n'a pas baissé significativement encore qu'une di-
minution ait été observée dans sept cas. Six malades avaient des
signes radiologiques d'osteodystrophie rénale, deux d'entre eux ont
été améliorCs au cours de l'étude et trois malades ont développé
une ostéodystrophie. Les malades qui avaient des alterations os-
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seuses radiologiques avaient les concentrations les plus élevées
d'hormone parathyroldienne et Ia majorité était des femmes. Les
etudes morphométriques ont montré que Ia perte d'os au cours de
'étude est survenue surtout chez les malades du sexe masculin. Des
calcifications des tissus moos ont continue a apparaitre au cours de
l'étude. Bien que Ia réponse de quelques malades a une augmenta-
tion de Ia concentration de calcium dans Ic dialysat ait été favor-
able il a été impossible de prévoir Ic type de malade qui pourrait
bCnéficier de l'utilisation d'un dialysat contenant 7,0 mg/l00 ml de
calcium.
Renal bone disease presents a variable problem in
patients treated by regular hemodialysis [1], and the
severity and incidence of the bone disease differ from
center to center [2,3]. Although many factors such as
vitamin D intake and metabolism, calcium and phos-
phate balance, uremia and dialysis itself may contrib-
ute to the development of bone disease in dialysis
patients, it has been suggested that secondary hy-
perparathyroidism plays a prominent role [4—8]. Hy-
perparathyroid bone disease is commonly assessed
radiologically but radiologic examination is a poor
guide to the histologic incidence of this form of bone
disease [9,10]. Furthermore, it is difficult radio-
logically to define bone disease in terms of resorption,
failure of mineralization and change in bone mass.
Since the development of the radioimmunoassay
for parathyroid hormone in plasma [Ill, it has been
shown that nearly all patients with chronic renal
failure, whether dialyzed or not, have increased
concentrations of circulating parathyroid hormone
[2,12—14], and indeed the highest values recorded in
man are in patients with renal failure. In a study of
patients with chronic renal failure, lower concentra-
tions of plasma immunoreactive parathyroid hor-
mone (IPTH) were found in those patients with bone
disease than in those without bone disease [2]. How-
ever, other studies in dialysis patients have shown
higher concentrations of plasma IPTH in those
patients with bone disease [14]. It was also observed
that a higher incidence of renal bone disease occurred
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in patients treated with dialysate of low calcium con-
centration [14]. In short-term experiments the same
workers showed that increasing the concentration of
calcium in the dialysate could produce a significant
decrease in the concentration of IPTH in the blood of
their dialysis patients. In acute experiments using
extremes of dialysate calcium concentration of 3.5
and 8.5 mg/100 ml (i.e., outside the accepted thera-
peutic range), rapid changes of plasma IPTH concen-
trations, opposite to the dialysate calcium concentra-
tions, have been reported [15]. It has been suggested,
therefore, that the incidence and progress of second-
ary hyperparathyroidism in regular dialysis patients
can be reduced by the use of a dialysate of high
calcium concentration. Goldsmith et al [16] consid-
ered that the optimal dialysate calcium concentration
to suppress IPTH concentration and prevent second-
ary hyperparathyroid bone disease was 8.0 mg/100
ml.
It is a widely accepted practice [17,18] to use dialy-
sate containing calcium in a concentration of 6.0
mg/lOO ml in maintenance hemodialysis. At this con-
centration it has been reported that the patient is in
moderate positive calcium balance but does not be-
come hypercalcemic [18].
The present work was undertaken to determine (a)
whether increasing the concentration of calcium in
the dialysate would influence IPTH concentration
when used on a long-term basis, (b) whether a higher
concentration of dialysate calcium could be used
without causing unacceptable hypercalcemia or soft
tissue calcification (STC) and (c) whether the radio-
logic changes in bone could be influenced by increas-
ing the dialysate calcium concentration.
Methods
The 20 patients (ten men and ten women, aged 21
to 52 yr) in this study were unselected and had
chronic end-stage renal failure treated by regular
hemodialysis. Their clinical and biochemical data are
shown in Table 1. The duration of renal failure was
dated from the first recorded elevation of the blood
urea concentration while the duration of renal disease
was in many cases known to be longer.
Before the study commenced, dialysate calcium
concentration was either 4,5 or 6.0 mg/l00 ml and
the period during which the latter calcium concentra-
tion was used before changing to 4.5 mg/l00 ml is
indicated in Table I. At the beginning of the study, all
patients used a dialysate calcium concentration of 4.5
mg/l00 ml. The patients were studied at the end of
nine months but seven patients entered the study
during this period (Table 1) and therefore completed
less than nine months. All patients were again studied
after ten months at a dialysis calcium concentration
of 6 mg/l00 ml, and then after five months at 7
mg/l00 ml. There were no significant differences be-
tween the patients who had previously been dialyzed
with dialysate calcium concentrations of 4.5 and 6.0
mg/l00 ml in respect to either plasma calcium, phos-
phate, alkaline phosphatase, IPTH or the presence or
absence of bone disease.
Kiil dialyzers were used during three ten-hour ses-
sions per week. Dialysate was produced by propor-
tionate pumping of deionized water, or water passed
through a water-softener, and concentrates which
were manufactured by the hospital pharmacy depart-
ment to yield the three required concentrations of
calcium. The concentration of magnesium in the
dialysate was 1.09 mg/l00 ml and the fluoride con-
centration was low but not measured. Individual
single-pass systems were used with dialysate flow
rates of 500 mI/mm.
All of the patients took a multivitamin preparation
containing vitamin D2, 900 I.U. daily. Two patients
received extra vitamin D2; one (patient 5) with no
radiologic bone disease received 100,000 I.U. daily
for four months and the other (patient 19), with bone
disease, received 25,000 1.U. daily for nine months.
The two patients stopped vitamin D2 one month and
four months, respectively, after the dialysate calcium
concentration was increased to 6.0 mg/l00 ml. One
individual (patient 14) with bone disease received
aluminum hydroxide continually throughout the
study and five patients (5, 7, 9, 16 and 17) for a short
period at the beginning of the study. All patients were
heparinized during hemodialysis and each received
60,000 I.U. of heparin per week.
Predialysis blood samples were taken monthly for
routine measurement of the concentrations of cal-
cium, phosphate, electrolytes and alkaline phospha-
tase. In addition, predialysis blood samples were ana-
lyzed at the end of each period of the study. The
blood was immediately centrifuged and plasma total
calcium, phosphate and alkaline phosphatase con-
centrations were measured using standard Technicon
Auto-Analyser techniques. Plasma samples were fro-
zen and stored at —38°C for measurement of para-
thyroid hormone (PTH). PTH concentration was
measured by radioimmunoassay using a modification
of the original method [111. The antiserum used was
raised in guinea pigs against a partially purified prep-
aration of bovine PTH (1—84 residues), and the PTH
tracer was prepared by labelling CMC-purified bo-
vine PTH with 125iodine. Bound and free hormone
was separated by charcoal and both fractions were
counted. The three plasma samples in each patient
were run in quadruplicate (i.e., from the 4.5, 6 and 7
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Table 1. Initial data on the patients studied (dialysate calcium concentration, 4.5 mg/100 ml)
mg/100 ml dialysate calcium study) in the same assay
and the results were expressed in ng/ml of plasma in
terms of human PTH extracted from parathyroid
adenomata. The range in normal subjects using the
same antibody is 0.5 to 1.5 ng/ml and the plasma
concentrations in 90% of patients with primary hy-
perparathyroidism lie outside the normal range [19].
Radiologic signs were assessed by examination of
x-ray films of hands, shoulders, skull, pelvis, dorsal
and lumbar spines and femora. The criteria for the
diagnosis of bone disease were (1) presence of sub-
periosteal erosions, (2) presence of Looser's zones.
STC was assessed in vessels, around joints and
elsewhere.
Sixteen patients had bone surveys during the initial
period of dialysis with a dialysate calcium concentra-
tion of 4.5 mg/l00 ml; all the patients had bone
surveys at the end of the period of dialysis with a
dialysate calcium concentration of 6.0 mg/100 ml;
and 19 patients had surveys at the end of the period
of dialysis with a dialysate calcium concentration of
7.0 mg/lOO ml, Appearances in repeat surveys were
classified as new, improved, worse or unchanged.
The loss of bone from the metacarpals of each
patient was evaluated by performing morphometric
measurements on pairs of hand radiographs by the
method of Horsman and Nordin [20]. Pairs of radio-
graphs were available for all patients, some having
only two pairs, others as many as six pairs. The first
pair and last pair had been taken at intervals ranging
from nine months to 3½ yr. The total width and
medullary width at the midshaft of the second, third
and fourth metacarpals of both hands were measured
in duplicate using needle-tipped Vernier calipers. A
full description of this method is given elsewhere [211.
For each patient the changes in the mean total width
and cortical width of the six metacarpals were eval-
uated. The changes are denoted by TW, MW and
CW, respectively.
Results
The clinical and biochemical data obtained in the
20 patients at the end of the period of dialysis with a
dialysate calcium concentration of 4.5 mg/l00 ml
(initial data) are shown in Table 1. There were no
significant differences between the groups with and
Duration of dialysis, yr
Plasma PlasmaAt dialysate
Before dialysate calcium conc. alkaline immunoreactive
Renal calcium conc. of 6 mg/l00 ml Plasma Plasma phosphatase parathyroid
Patient Age failure increased to before decrease calcium phosphate King-Armstrong hormone
No. Sex yr yr 6mg/100m1 to4.Smg/lOOml mg/lOOm! mg/100 ml U/lOOm! ng/ml
Patients without radiologic bone disease
I M 48 0.1 0.1 0 8.6 5.6 5 4.4
2 F 51 I 0.1 0 8.0 3.9 13 5.6
3 M 32 0.1 0.3 0 10.1 5.0 6 2.2
4 M 40 5 1.3 0.5 9.9 4.7 10 7.4
5 F 34 3 3.5 1.5 10.6 5.8 9 8.2
6 F 23 I 0.8 0 10.3 3.5 12 9.6
7 M 43 2 0.9 0 8.9 6.5 9 3.4
8 M 52 0.3 1.5 0.7 7.6 5.3 12 5.1
9 M 24 2 1.5 0.7 10.0 5.2 Il 4.8
10 F 42 0.2 1.5 0 9.5 4.6 9 4.7
II M 30 0.2 0.1 0 10.8 6.8 6 3.5
Mean 38.1 1.3 1,1 0.3 9.5 5.2 9.3 5.4
SEM — — — — 0.3 0.3 0.8 0.6
12 F 52 0.1
Patients with radiologic bone disease
0.4 0 10.6 3.3 8 9.5
13 F 49 0.1 3.3 2.4 9.0 5.4 13 11.2
14 M 43 5 2.3 0.6 9.6 4.6 20 14.2
15 F 21 3 0.2 0 10.1 10.2 9 11.4
16 F 23 2 1.0 0.3 9.3 4.4 6 11.6
17 F 24 3 1.8 0 8.6 5.4 12 8.8
18 M 39 0.2 3.3 2.4 9.1 6.6 13 10.8
19 M 29 3 4.0 1.3 9.7 4.1 29 6.4
20 F 43 1.5 0.2 0 7.8 5.8 9 13.9
Mean 35.9 2.0 1.8 0.8 9.3 5.5 13.2 10.9
SEM — — — — 0.3 0.7 2.3 0.8
Mean 37.1 1.7
All patients
1.4 0.5 9.4 5.3 11.1 7.9
SFM — — — — 0.2 0.3 1.2 0.8
aFor convenience the patients are divided into two groups according to the presence of radiologic evidence of bone disease.
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Table 2. Relationship to dialysate calcium of plasma calcium, plasma phosphate and plasma alkaline phosphatase in the patientsa
Dialysate
calcium
mg/lOO ml
Plasma calcium
rng//OO ml
Plasma phosphate
mg/IOO ml
Plasma alkaline
phosphatase
KA U/lOO ml
PredialysisPredialysis Postdialysis Predialysis Postdialysis
4.5
6.0
7.0
9.4 0.21 8.7 0.24
9.7 0.20 10.2 0.19
10.0 + 0.16 10.6 + 0.15
5.3 + 0.34 2.8 + 0.23
5.6 0.39 3.5 0.18
5.6 0.40 3.9 0.22
11.2 1.2
11.7 2.1
11.1 + 1.9
a Results are expressed as mean + SEM.
without radiologic evidence of bone disease with re-
spect to age, duration of renal failure or duration of
dialysis before the study. Six female patients had
radiologic bone disease whereas only three male
patients had radiologic bone disease.
Plasma calcium. The initial predialysis plasma cal-
cium concentrations ranged from 7.6 to 10.8 mg/l00
ml and were unrelated to the concentrations of
plasma phosphate, alkaline phosphatase and IPTH
and to the presence or absence of radiologic bone
disease. There was no difference in the initial pre-
dialysis plasma calcium concentrations between the
male and female patients. On increasing the dialysate
calcium concentration from 4.5 to 6.0 mg/lOO ml,
there was a significant increase (P < 0.05) in the
mean predialysis plasma calcium concentration from
9,4 to 9.7 mg/l00 ml (Table 2). When the dialysate
calcium concentration was increased from 6.0 to 7.0
mg/100 ml, the mean predialysis plasma calcium in-
creased from 9.7 to 10.0 mg/lOO ml (P < 0.05) (Table
2). The routine monthly blood samples showed a
similar rise in plasma calcium as the dialysate calcium
was increased from 4.5 to 6 to 7 mg/100 ml. The
changes in predialysis plasma calcium concentration
were not significantly different in the groups with and
without radiologic evidence of bone disease (Table
3), or between male and female patients. The increase
in plasma calcium on increasing the dialysate calcium
concentration was also related to the initial plasma
calcium such that patients with lower initial plasma
calcium concentrations produced the greater in-
creases (P < 0.01). The mean postdialysis plasma
calcium concentration was lower than the predialysis
value at a dialysate calcium concentration of 4.5
mg/lOO ml but was higher than the predialysis values
at dialysate calcium concentrations of 6.0 and 7.0
mg/100 ml (Table 2 and Fig. 1).
Plasma phosphate. The initial mean plasma phos-
phate of the patients was elevated at 5.3 mg/100 ml
and increased but not significantly to 5.6 mg/lOO ml
when the dialysate calcium concentration was in-
creased from 4.5 to 6.0 mg/100 ml. No further
change in the mean plasma phosphate occurred on
increasing the dialysate calcium concentration from
6.0 to 7.0 mg/100 ml (Table 2). However, the changes
in plasma phosphate concentration in individual
patients were related to their initial plasma phosphate
concentration such that patients with lower initial
plasma phosphate concentrations produced the
greater increases (P < 0.05). There were no signifi-
cant differences between the groups with and without
bone disease (Table 3), or between male and female
patients.
Plasma alkaline phosphatase. Two patients had ele-
vated alkaline phosphatase concentrations at the be-
ginning of the study and both had radiologic evidence
of bone disease. The mean plasma alkaline phospha-
tase concentration was higher in the group with bone
disease but was only significant at the two higher
concentrations of dialysate calcium (P < 0.02 and P
< 0.05, respectively.) The mean plasma alkaline
phosphatase concentration did not change signifi-
Table 3. Concentrations of plasma calcium, phosphate and alkaline phosphatase at the three concentrations of dialysate calcium studied
in patients without and with radiologic bone diseasea
Dialysate calcium
mg/lOU ml
Predialysis plasma calcium
mg/IOU ml
Predialysis plasma phosphate
mg/IOU ml
Predialysis plasma
alkaline phosphatase
KA U/IOU ml
No bone disease Bone disease No bone disease Bone disease No bone disease Bone disease
4.5
6.0
7.0
9.5 + 0.34 9.3 0.28
9.7 0.27 9.7 0.30
10.0 + 0.27 10.0 0.20
5.2 0.30 5.5 0.67
5.5 0.63 5.8 0.43
6.0 0.63 5.2 + 0.40
9.1 0.81 13.1 2.4
6.9 + Ø96b 16.9 4.1
7.3 + 0•90b 15.6 + 3.7
a Results are expressed as mean SEM.
For significance of difference at 6.0, P < 0.02; and at 7.0, P < 0.05.
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cantly throughout the study (Table 3). Altogether six
patients had increased alkaline phosphatase concen-
trations at some time during the study, five of them
with radiologic evidence of bone disease.
Plasma IPTH. The concentration of plasma IPTH
was high in all patients at all three levels of dialysate
calcium concentration. It was significantly higher (P
<0.01) in the group with radiologic evidence of bone
disease than in the group without bone disease (Fig.
2). It was also significantly higher in the female
patients (P < 0.05), The mean predialysis plasma
IPTH did not change significantly when the dialysate
calcium concentration was increased (Table 4). There
was a tendency for the mean plasma IPTH concentra-
tion to decrease in the group without bone disease
but the change was not significant.
Considering the patients individually, in seven
(patients 1, 6, 7, 9, 10, 19 and 20) there was a decrease
in IPTH and, of these, only two had radiologic evi-
dence of bone disease (patients 19 and 20). Ten
patients showed no change in IPTH concentration
and three individuals (patients 4, 12 and 17) showed
an increase (see Table 4). Plasma IPTH concentra-
tion was not related to predialysis plasma calcium
8
I _____ I
Before After Before After Before After
4.5 mg/i 00 ml 6.0 mg/i 00 ml 7.0 mg/i 00 ml
Fig. I. Plasma calcium (mean SEM) before and after dialysis in all
patients at the three concentrations of dialysate calcium.
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Fig. 2. Plasma JPTH in patients without (S) and patients With (0)
radiologic bone disease (at a dialysate calcium concentration of 4.5
mg/100 ml).
concentration or plasma phosphate concentration at
any level of dialysate calcium concentration. There
was no relationship between the change in plasma
IPTH concentration from the initial concentration (
IPTH) and the corresponding change in plasma cal-
cium concentration (z Ca) when all the patients were
considered together or when the patients with and
without bone disease were considered separately. The
change in plasma IPTH concentration was also unre-
lated to the change in plasma phosphate concentra-
tion and to any change found in bone morphometry.
E
I
10
j \\\
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Table 4. Plasma IPTH (ng/ml) in patients without and with
radiologic bone disease at the three concentrations of dialysate
calcium
Patient No.
Dialysate Dialysate Dialysate
calcium calcium calcium
4.5 mg/100ml 6.0 mg/l00 ml 7.0 mg/l00 ml
Patients without radiologic bone disease
I 4.5 3.4 2.7
2 5.6 3.6 5.1
3 2.2 3.0 2.1
4 7.4 7.7 8.7
5 8.2 8.3 8.4
6 9.6 7.8 6.6
7 3.4 3.2 1.9
8 5.1 4.1 5.1
9 4.8 5.0 3.4
10 4.7 3.4 3.0
11 3.5 3.9 3.8
Mean 5.35 4.85 4.62
SEM 0.64 0.59 0.69
Patients with radiologic bone disease
12 9.5 10.3 11.8
13 11.2 12.9 12.8
14 14.6 10.9 12.7
15 11.4 9.7 12.1
16 11.6 9.3 10.9
17 8.8 11.8 14.1
18 10.8 10.5 11.4
19 6.4 6.2 4.9
20 13.9 12.5 11.3
Mean 10.91 10.46 11.35
SEM 0.79 0.63 0.82
All patients
Mean 7.86 7.38 7.64
SEM 0.79 0.76 0.91
Radiology. All nine patients with radiologic bone
disease had subperiosteal erosions of the hands and
one (patient 16) also had Looser's zones. Three
patients (16, 17 and 18) developed subperiosteal ero-
sions during the period of dialysis with fluid contain-
ing a calcium concentration of 6.0 mg/100 ml, but the
other six patients had roentgenographic evidence of
bone disease during the initial period. One of these
(patient 20) showed worsening of the bone signs dur-
ing the second period at a dialysate calcium concen-
tration of 6.0 mg/l00 ml and another (patient 12)
worsened during the third period (dialysate calcium
concentration, 7.0 mg/tOO ml). Two patients (13 and
14) showed improvement with partial healing of ero-
sions during the final period when the dialysate cal-
cium concentration was 7.0 mg/100 ml and in the
remaining two (patients 15 and 19) the bone signs did
not change. There was no clinical or radiologic evi-
dence of fracture during the period of study.
The presence of bone changes on roentgenogram
was not related to the age of the patients, but there
was a sex difference; six of ten female patients had
bone disease whereas only three of ten male patients
had bone disease. Although there was a tendency for
bone disease to be related to the duration of renal
failure and the duration of maintenance hemo-
dialysis, neither association was statistically signifi-
cant (Table I). Of the five patients whose bone dis-
ease appeared or progressed during the study, two
(patients 12 and 17) showed progressive increases in
plasma IPTH concentrations.
Vascular calcification was present in 11 patients at
their first survey and was observed in three others
(patients 1, 7 and 17) at the end of the period of
dialysate calcium concentration of 6.0 mg/l00 ml.
Periarticular soft tissue calcification (SIC) was seen
in six patients, in two (patients 9 and 19) at their first
survey, in three (patients 6, 16 and 18) at the end of
the 6.0 mg/tOO ml period and in another (patient 3)
at the end of the 7.0 mg/l00 ml period. One patient
(9) who had periarticular calcification at the initial
examination showed a progressive increase in the size
of deposits and developed pulp space calcification in
the hands during the 7.0 mg/100 ml period. The
presence of SIC was not related to the presence of
bone disease, predialysis plasma concentrations of
calcium and phosphate, alkaline phosphatase, IPTH
or the calcium phosphate product.
The two patients whose erosions partially healed
showed increases in plasma calcium and one showed
a fall in alkaline phosphatase from abnormal to nor-
mal concentrations, but neither had any significant
change in plasma IPTH.
Morphometry. The results of the morphometric
measurements performed on the first and last pairs of
hand radiographs available on each patient are
shown in Fig. 3 a, b and c. The changes in mean total
width of the metacarpals, , are plotted against
time in Fig. 3 a, with all patients referred to a com-
mon time origin. In the majority of patients, the
observed changes in TW lie within the error range
of the method. There appears to be a significant
increase in TW in four patients (P < 0.05) and a
significant decrease in four patients, but in each case
the change is only just outside the error range.
The changes in mean medullary width of the meta-
carpals, XMW, are shown similarly in Fig. 3 b.
Marked increases in medullary width have occurred
in a number of patients. Endosteal bone loss appears
to have occurred in all but one of the male patients,
the loss being significant in five out of the ten cases.
The female patients are much less consistent, with an
apparent loss in six women, a gain in three and no
change in one patient.
The changes in mean cortical width, are
shown in Fig. 3 c, and reflect the summated effects of
bone gain and loss at the periosteal and endosteal
surfaces. The data show that net bone loss has oc-
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curred in all the men, the loss being significant in
seven out of the ten cases, and that no consistent loss
occurred in the women.
Figure 4 a and b contains a more detailed presenta-
tion of the changes in cortical width. In this diagram,
the changes are shown for all available pairs of films.
In contrast to Fig. 3, the patients have not been
referred to a common time origin; instead, the data
are plotted against date, the vertical lines separating
the periods within which the dialysate calcium con-
centration was 4.5, 6.0 and 7.0 mg/100 ml, Figure 4 a
shows the progressive losses which occur in the ma-
jority of males irrespective of the increasing dialysate
calcium concentration. One striking exception is
patient 14, who had a significant loss of bone during
the first period (—CW, 0.1 mm; P <0.05) but had a
progressive improvement during the second and third
periods when the dialysate calcium concentration was
6.0 and 7.0 mg/tOO ml. The female data are shown in
Fig. 4 b. In eight of the nine patients observed within
either or both of the first two periods when the dialy-
sate calcium concentration was 4,5 and 6.0 mg/l00
ml, bone loss occurred, although the loss is signifi-
cant in only three cases. In contrast, in the third
period, only three of the nine patients lost bone, none
of the losses being significant; in six of the nine
patients who gained bone, the increase is significant
in two.
Discussion
The incidence of bone disease varies widely among
dialysis centers from a low [22,23] to a very high
incidence [6,7]. The variation is partly due to differ-
ences in the criteria and the methods used to define
bone disease. It is clear, for example, that radiologic
techniques underestimate the incidence of histologic
bone disease [9,10,24]. However, in a survey in-
volving two dialysis centers in the same country, an
incidence in bone disease of 35% was found at one
center whereas at the other it was 68% [2]. Not only is
there a variation in the incidence, but there is also a
variation in the type of bone disease prevalant at
different centers. At some, the predominant form
seems to be a loss of bone mass associated with a high
fracture rate [25—27], whereas at others, hyperpa-
rathyroid bone disease is the commonest form [6,7].
In the dialysis patients we have reported here, radio-
logic evidence showed an incidence of bone disease of
45% which was considered to be predominantly of the
hyperparathyroid type.
The reasons for these variations have never been
adequately explained. It is thought by some that
fluoride may be a factor [25,27,28] but no conclusive
evidence is available that fluoride in the dialysate
yr
Fig. 3. Changes in total (a) medullary (b) and cortical (c) widths of
metacarpals in all patients between the first and last radiographs.
determines the incidence and type of bone disease. In
the present series the fluoride content of the dialysate
was low. It has also been suggested that the loss of
bone mass and high fracture rate are more common
in patients who do not use a water-softener for the
preparation of the dialysate [27,28] and it has been
reported that the use of deionized water instead of
water treated with a "water-softener" can promote
the healing of the bone disease [28]. In our patients
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Fig. 4. Changes in cortical widths of metacarpals shown in relation
to dialysale calcium concentration.
some used deionized water throughout the study
whereas others used a water-softener and no patient
used untreated "tap" water. There was, however, no
difference in the incidence or type of bone disease or
in the plasma biochemistry in the two groups of
patients, and it seems unlikely therefore that the use
of deionized water for preparing the dialysate fluid
influenced the results of the present study. Heparin
has been reported to cause osteoporosis [29] and
since it is used universally in hemodialysis it has been
considered to be a possible cause of the loss in bone
mass. The dose of heparin which might cause os-
teoporosis is considered to be greater than 50,000 to
70,000 U/week. Our patients used 60,000 U/week
which is similar to the amount used in other centers
which have reported both high and low incidences of
bone disease.
The age of the patients was not a significant factor
in determining the presence or severity of bone dis-
ease, but there was a tendency for the presence of
bone disease to be related to the duration of renal
failure and to the duration of dialysis treatment [2,81.
The incidence of radiologic bone disease was higher
in the females than in the males [6,3]. This contrasts
with other studies [2,27] in which males were more
commonly affected. The type of bone disease in these
studies, however, was characterized by bone loss and
fracture and relatively low plasma IPTH concentra-
tions [2], tt may be, therefore, that female patients
tend to develop hyperparathyroid bone disease with
high IPTH concentrations whereas male patients
tend to develop osteopenic bone disease with rela-
tively low IPTH concentrations. In the present study
the males showed an increase in bone loss as judged
by morphometric measurements, and low IPTH con-
centrations as compared to the females. The fact that
bone loss is associated with relatively low IPTH con-
centrations suggests that the bone loss is primary and
indeed may be responsible for the relatively low
IPTH concentrations. It is not clear from the present
study what factors are responsible for the increased
bone loss in the male patients. It could be argued the
male patients are more susceptible to the relative
immobilization which occurs in dialysis. They may
also be more susceptible to bone resorption induced
by high doses of vitamin D. However, only two of
our patients were on high doses of vitamin D during
the study one was male and the other female
(patients 19 and 5, respectively) and both showed
increased bone loss.
Plasma alkaline phosphatase was increased in five
of the nine patients with radiologic bone disease and
in one of the patients without. It seems that an in-
creased alkaline phosphatase strongly suggests the
presence of bone disease but that patients with bone
disease may have normal concentrations of alkaline
phosphatase [24,30].
The finding that plasma IPTH concentrations were
higher in patients with radiologic bone disease than
in those without is similar to that of other workers
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[14] and suggests that raised IPTH concentrations are
important in the etiology of some forms of bone
disease in hemodialysed patients. On the other hand,
another study has shown that patients with bone
disease have lower IPTH concentrations than those
without bone disease [2], but as discussed above it
seems likely that the major component in the bone
disease of those patients was different from that in
ours. In only two of the patients was the worsening of
the bone disease associated with an increase in IPTH
concentration and in the two patients who showed
partial healing, IPTH did not change significantly.
Since it is well documented that bone disease is re-
lieved by parathyroidectomy [8,9], it is likely that our
results probably represent the great difficulty in as-
sessing the presence and progress of bone disease by
radiologic techniques, especially over relatively short
time periods.
The morphometric measurements provide infor-
mation on the events occurring at both the periosteal
and endosteal surfaces. There is no evidence to sug-
gest that the external dimensions of the bone changed
in either sex within the period of observation and in
this respect the patients do not differ from normal
subjects. The changes at the endosteal surface ob-
served in the female patients were variable with a
suggestion that at the highest concentrations of dialy-
sate calcium the rate of bone loss was reduced. In the
male patients, however, there was a progressive loss
of bone which was not affected by increasing the
dialysate calcium concentration.
The pre- and postdialysis calcium concentration
rose significantly in our patients on increasing the
dialysate calcium. This agrees with the results ob-
tained by other workers [16], although it has been
shown [31] that even with dialysate calcium of 8
mg/lOO ml only the postdialysis plasma calcium
concentration rose. In our patients when the dialysate
calcium was 4.5 mg/l00 ml, the postdialysis plasma
calcium concentration was lower than the predialysis
calcium suggesting a loss of calcium, whereas with a
dialysate calcium of 6.0 and 7.0 mg/l00 ml, the post-
dialysis calcium was higher than the predialysis value,
suggesting positive balance. The patients with the
lowest initial plasma calcium concentration showed
the greatest increase in plasma calcium on increasing
dialysate calcium, which is in agreement with the data
from calcium flux studies during dialysis [16] showing
that calcium transfer from dialysate to plasma during
dialysis was proportional to the dialysate calcium
concentration.
Although there was a significant increase in plasma
calcium concentration, suppression of plasma IPTH
was not seen in the present study. The failure of
IPTH in some patients to become suppressed is not in
agreement with other studies [16]. On the other hand,
it is compatible with other observations [31] that
raising the dialysate calcium concentration to 8
mg/lOO ml did not decrease bone resorption rates
suggesting that PTH secretion had not been signifi-
cantly suppressed. Our results may indicate that the
parathyroid glands in many of our patients are not
responsive to normal feedback control mechanisms
and are "autonomous" [32,33]. They may also in-
dicate that the antibody used to measure IPTH in the
present study had difficulty in measuring small de-
creases in the biologically active hormone against a
high background of inactive hormonal fragments [34]
which have a very long half-life in renal failure
patients [35]. In the studies which have shown sup-
pression of IPTH to an increased dialysate calcium
[16], the plasma phosphate was maintained at a lower
concentration by means of phosphate binders than it
was in the present study. Although plasma phosphate
can only stimulate IPTH indirectly through its effect
on plasma calcium [36], the rise in plasma phosphate
produced by raising the dialysate calcium concentra-
tion [31] (especially in those patients who had rela-
tively low initial plasma phosphate) may have made
IPTH suppression more difficult to monitor. Indeed,
the rise in plasma phosphate may partly explain why
some patients increased the IPTH concentrations
during the study.
Although a minority of the patients did respond to
an increase in plasma calcium by a decrease in plasma
IPTH concentration, it was impossible to predict
which patients would respond in this manner. The
observed changes in IPTH were not correlated with
radiologic or morphemetric changes although it is
clear that the patients with radiologic bone disease
had the higher IPTH concentrations.
It appears that improvement as judged by a de-
crease in plasma IPTH or a decrease in the rate of
loss of bone mineral was related in only some patients
to the use of dialysate calcium of 7 mg/100 ml. In
some patients, however, there was worsening of the
bone disease, a failure of IPTH to decrease and the
progressive appearance of metastatic calcification.
There does not at present appear, therefore, to be a
method of distinguishing those patients who will re-
spond favorably to an increased dialysate calcium
concentration from those whose response may be
unremarkable or even unfavorable.
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